Intramuscular recombinant Erwinia asparaginase active, safe in leukemia, lymphoma subsets
Click Here to Manage Email Alerts
A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.
Results of the Children’s Oncology Group AALL1931 study — presented at ASCO Annual Meeting — showed a positive benefit-risk profile of the agent (Rylaze, Jazz Pharmaceuticals) when administered in a 3-day-a-week dosing schedule.
The safety profile appeared consistent with that of other asparaginases.
Luke Maese, DO, associate professor of pediatrics at University of Utah Huntsman Cancer Center and Primary Children’s Hospital, spoke with Healio about the study rationale, the potential implications of the findings and the questions that must be addressed in future research.
Reference:
Maese LD, et al. Abstract 7001. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Collapse
Healio Interview
Click Here to Manage Email Alerts